The offering provides ~$55.8M to fund pipeline development through key catalysts (AX-0810 Phase 1 data year-end 2026, AX-0811 CTA mid-2026). The positive Phase 1 data partially offsets dilution, but the 30% share count increase is a headwind. Monitor trading post-offering for stabilization; the 60-day lock-up limits near-term insider selling. Lilly's participation provides a floor but does not eliminate dilution overhang.
Price Chart
Executive Summary
ProQR is conducting a ~$50M underwritten public offering of 27.6M shares at $1.81, with a concurrent $9.2M private placement to Eli Lilly at the same price, totaling ~$55.8M in net proceeds. The offering is dilutive (~30% share count increase) but comes alongside positive Phase 1 data for lead asset AX-0810 announced the same day, showing target engagement and safety. Lilly's participation signals continued strategic support.
Key Facts
- Offering of 27,624,310 ordinary shares at $1.81 per share, gross proceeds of $50,000,001
- Concurrent private placement to Eli Lilly of 5,100,780 shares at same price, no underwriting discounts
- Total estimated net proceeds of ~$55.8 million after underwriting discounts and expenses
- Shares outstanding post-offering: 141,119,032, a ~30% increase from ~108.4M pre-offering
- Dilution of $1.11 per share to new investors (offering price $1.81 vs as-adjusted net tangible book value $0.70)
- Positive Phase 1 MAD data for AX-0810 announced June 25, 2026: up to 8-fold TBA increase, favorable safety, 8-week half-life
- Lilly maintains pro rata beneficial ownership via concurrent private placement
- 60-day lock-up for company and insiders; no ATM sales for 30 days
- Company has $75M at-the-market facility with Cantor (unused during lock-up period)
Financial Impact
~$55.8M net proceeds raised, diluting existing shareholders by ~30% with $1.11 per share dilution
Risk Factors
- Immediate dilution of ~30% to existing shareholders
- Clinical-stage biotech with no approved products; pipeline execution risk
- Potential need for additional financing beyond this raise
- PFIC status may create adverse tax treatment for U.S. holders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-077891 |
| Document: 0001104659-26-077891-index-headers.html | 0001104659-26-077891 |
| Document: 0001104659-26-077891-index.html | 0001104659-26-077891 |
| Document: 0001104659-26-077891.txt | 0001104659-26-077891 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.34 (−21.18%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.34 (−32.66%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.34 (+19.76%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.34 (+12.42%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.34 (−12.42%) |
Jun 2, 2026 21w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.34 (−8.84%) |
May 12, 2026 24w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.34 (+16.25%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.34 (−14.65%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.34 (−14.65%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.34 (−32.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers